Aegis wins US Patent for Triptan nasal spray formulations

Triptans are a class of drugs that are effective in treating migraine headaches which comprise sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan.

The clinical data presented in the issued patent claims that Intravail formulation of sumatriptan achieves equivalent drug levels at two to three minutes, 20 to 30 times faster that the presently marketed non-injectable sumatriptan products.

Aegis Therapeutics is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses.